Formulation and Evaluation of Eribulin Cubosomes for the Treatment of Breast Cancer

Abstract

Author(s): S. Alexandar1, Hari Veluru2, Ramu Samineni3, Kommu Pradeep4, Ram Mohan Manda5, Azmath Farhana6, Dileep Kumar Garnipudi7*

Breast cancer remains one of the leading causes of cancer-related mortality in women worldwide. Eribulin, a microtubule inhibitor, has shown promising therapeutic effects against metastatic breast cancer. However, its clinical efficacy is often limited by poor aqueous solubility and systemic toxicity. The present study aims to develop and evaluate Eribulin-loaded cubosomes to enhance its bioavailability, targeted delivery, and therapeutic efficacy. Cubosomes, which are bicontinuous cubic phase nanoparticles, provide a unique nanostructured delivery system with enhanced drug encapsulation and controlled release properties. The formulated cubosomes were characterized for their particle size, zeta potential, entrapment efficiency, in vitro drug release, cytotoxicity, and in vivo pharmacokinetic studies. The results demonstrated that Eribulinloaded cubosomes exhibit sustained drug release, improved cellular uptake, and enhanced antitumor activity compared to free drug formulations, indicating their potential as an effective nanocarrier for breast cancer treatment.

Share this article